Axovant Sciences Ltd. (AXON) Reports Q1 Loss of $0.35, Names CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Axovant Reports Financial Results for the First Fiscal Quarter of 2015 and Provides Corporate Update
August 11, 2015 4:05 PM EDTHAMILTON, Bermuda, Aug. 11, 2015 /PRNewswire/ --Â Axovant Sciences Ltd. (NYSE:Â AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today reports financial results for the first fiscal quarter ended June 30, 2015.
Cash totaled $331.1 million at June 30, 2015, and net cash used in operating activities was $4.5 million for the quarter. The gross proceeds of Axovant's initial public offering (IPO) on the New York Stock Exchange (NYSE) in June 2015 were $362.3 million, prior to underwriting discounts and commissions and offering expenses of $27.7 million.
For the first fiscal quarter... More
